J C Stevenson

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. doi Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety
    John C Stevenson
    National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London SW3 6NP, UK
    Maturitas 76:10-21. 2013
  2. ncbi Oral versus non-oral hormone replacement therapy: how important is the route of administration?
    Stevenson C John
    National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London, UK
    Ginekol Pol 78:514-20. 2007
  3. ncbi HRT and the primary prevention of cardiovascular disease
    John C Stevenson
    National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London, UK
    Maturitas 57:31-4. 2007
  4. ncbi Breast cancer and HRT: general practice must not pick up the wrong pieces
    J C Stevenson
    Endocrinology and Metabolic Medicine, Faculty of Medicine, Imperial College London, Mint Wing, St Mary s Hospital, Praed Street, London W2 1NY, UK
    Maturitas 46:109-10. 2003
  5. ncbi Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers
    John C Stevenson
    Endocrinology and Metabolic Medicine, Faculty of Medicine, Imperial College London, St Mary s Hospital, UK
    Br J Haematol 124:802-8. 2004
  6. ncbi HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?
    John C Stevenson
    National Heart and Lung Division, Faculty of Medicine, Imperial College London, Royal Brompton Hospital, UK
    Hum Reprod 21:1668-71. 2006
  7. ncbi A new hormone replacement therapy containing a progestogen with anti-mineralocorticoid activity
    John C Stevenson
    National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London, UK
    J Br Menopause Soc 12:8-10. 2006
  8. ncbi The metabolic basis for the effects of HRT on coronary heart disease
    John C Stevenson
    Reader and Consultant Metabolic Physician, Imperial College London, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
    Endocrine 24:239-44. 2004
  9. ncbi Hormone replacement therapy: review, update, and remaining questions after the Women's Health Initiative Study
    John C Stevenson
    Endocrinology and Metabolic Medicine, Faculty of Medicine, Imperial College London, Mint Wing, St Mary s Hospital, Praed Street, London W2 1NY, UK
    Curr Osteoporos Rep 2:12-6. 2004
  10. ncbi Justification for the use of HRT in the long-term prevention of osteoporosis
    John C Stevenson
    National Heart and Lung Division, Faculty of Medicine, Imperial College London, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
    Maturitas 51:113-26. 2005

Collaborators

Detail Information

Publications45

  1. doi Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety
    John C Stevenson
    National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London SW3 6NP, UK
    Maturitas 76:10-21. 2013
    ..HRT plays an important role in improving and maintaining women's health when used appropriately. ..
  2. ncbi Oral versus non-oral hormone replacement therapy: how important is the route of administration?
    Stevenson C John
    National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London, UK
    Ginekol Pol 78:514-20. 2007
    ..Based on current evidence transdermal HRT may also cause more irregular and breakthrough bleeding with sequential and continuous therapies than oral counterparts...
  3. ncbi HRT and the primary prevention of cardiovascular disease
    John C Stevenson
    National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London, UK
    Maturitas 57:31-4. 2007
    ..Whilst the greatest CHD benefit may be seen by starting HRT in the early postmenopause, this does not exclude benefit in older women given appropriate low dose therapy...
  4. ncbi Breast cancer and HRT: general practice must not pick up the wrong pieces
    J C Stevenson
    Endocrinology and Metabolic Medicine, Faculty of Medicine, Imperial College London, Mint Wing, St Mary s Hospital, Praed Street, London W2 1NY, UK
    Maturitas 46:109-10. 2003
  5. ncbi Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers
    John C Stevenson
    Endocrinology and Metabolic Medicine, Faculty of Medicine, Imperial College London, St Mary s Hospital, UK
    Br J Haematol 124:802-8. 2004
    ..05) decreased, more so in the placebo group. There were no changes in matrix metalloproteinase (MMP)-2, or in LDL particle size. This transdermal HRT had beneficial effects on vascular function and CHD risk markers...
  6. ncbi HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?
    John C Stevenson
    National Heart and Lung Division, Faculty of Medicine, Imperial College London, Royal Brompton Hospital, UK
    Hum Reprod 21:1668-71. 2006
    ..Thus, no new safety issues have been identified, and the regulatory authorities may have misinterpreted the data from these recent studies. When given for the correct indications, HRT is of major benefit to many women...
  7. ncbi A new hormone replacement therapy containing a progestogen with anti-mineralocorticoid activity
    John C Stevenson
    National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London, UK
    J Br Menopause Soc 12:8-10. 2006
    ..The introduction of estradiol plus drospirenone may offer the opportunity to re-evaluate the contribution of the progestogen component of hormone replacement therapy...
  8. ncbi The metabolic basis for the effects of HRT on coronary heart disease
    John C Stevenson
    Reader and Consultant Metabolic Physician, Imperial College London, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
    Endocrine 24:239-44. 2004
    ..This concept needs to be tested as a priority before hormone replacement therapies are rejected as being of no cardiovascular benefit...
  9. ncbi Hormone replacement therapy: review, update, and remaining questions after the Women's Health Initiative Study
    John C Stevenson
    Endocrinology and Metabolic Medicine, Faculty of Medicine, Imperial College London, Mint Wing, St Mary s Hospital, Praed Street, London W2 1NY, UK
    Curr Osteoporos Rep 2:12-6. 2004
    ..Skeletal benefits have been confirmed in terms of fracture reduction, as has a small risk of breast cancer development. Further studies of other HRT regimens are urgently required to clarify the cardiovascular effects...
  10. ncbi Justification for the use of HRT in the long-term prevention of osteoporosis
    John C Stevenson
    National Heart and Lung Division, Faculty of Medicine, Imperial College London, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
    Maturitas 51:113-26. 2005
    ..In conclusion, HRT should currently be used only for women with climacteric symptoms or an increased risk of osteoporosis, and it is important that there is an individualised approach to treatment based on each woman's risk profile...
  11. doi HRT and cardiovascular disease
    John C Stevenson
    National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
    Best Pract Res Clin Obstet Gynaecol 23:109-20. 2009
    ..Women initiating HRT within 10 years of menopause onset may achieve cardiovascular benefit, particularly in terms of primary CHD prevention, whilst avoiding risks of stroke and venous thrombo-embolism...
  12. doi Hormone replacement therapy and cardiovascular disease revisited
    John C Stevenson
    National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
    Menopause Int 15:55-7. 2009
    ..The preliminary WHI results do not reflect accurately true benefits and risks, and HRT should remain a potential preventive treatment for CHD...
  13. doi Coronary heart disease and menopause management: the swinging pendulum of HRT
    John C Stevenson
    National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London, UK
    Atherosclerosis 207:336-40. 2009
    ..The raw data must be made available for independent assessment to obtain valid conclusions which may again change clinical practice...
  14. doi Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study
    John C Stevenson
    National Heart and Lung Institute, Imperial College London, Royal Brompton NHS Foundation Trust, London, UK
    Maturitas 67:227-32. 2010
    ..The primary aim of this double-blind, multi-centre, randomised study was to assess the efficacy of oral ultra-low dose continuous combined hormone replacement therapy with 17β-oestradiol and dydrogesterone...
  15. doi Prevention of osteoporosis: one step forward, two steps back
    John C Stevenson
    National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, UK
    Menopause Int 17:137-41. 2011
    ..New treatments are emerging, but again caution must be taken until any long-term adverse effects have been identified...
  16. doi A woman's journey through the reproductive, transitional and postmenopausal periods of life: impact on cardiovascular and musculo-skeletal risk and the role of estrogen replacement
    John C Stevenson
    National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London, UK
    Maturitas 70:197-205. 2011
    ..In this journey through a woman's life current best evidence relating to cardiovascular and musculo-skeletal risk will be reviewed in line with well documented management strategies...
  17. ncbi Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women
    I F Godsland
    Endocrinology and Metabolic Medicine, Faculty of Medicine, Imperial College London, London, UK
    Clin Endocrinol (Oxf) 60:541-9. 2004
    ..This study was undertaken to establish whether oral oestradiol plus dydrogesterone postmenopausal hormone therapy can modify these changes...
  18. ncbi The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone
    B Lees
    Endocrinology and Metabolic Medicine, Imperial College School of Medicine, St Mary s Hospital Campus, London, UK
    Osteoporos Int 12:251-8. 2001
    ..The lower dose of estradiol-17 beta is a particularly suitable treatment for osteoporosis management in older women since it should minimize side-effects and improve the acceptability of HRT...
  19. ncbi A comparison of the skeletal effects of goserelin and danazol in premenopausal women with endometriosis
    J C Stevenson
    Cavendish Clinic, London, UK
    Horm Res 32:161-3; discussion 164. 1989
    ..Danazol treatment is not associated with loss of bone. Prolonged or repeated courses of treatment with goserelin alone could lead to a clinically significant adverse effect on the skeleton...
  20. ncbi 17beta-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women
    J C Stevenson
    Endocrinology and Metabolic Medicine, Imperial College School of Medicine, W2 INY, London, UK
    Maturitas 38:197-203. 2001
    ..The lower dose of oestrogen and the avoidance of cyclical bleeding make this a particularly suitable regimen for the prevention and treatment of osteoporosis in older women...
  21. ncbi 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women
    J C Stevenson
    National Heart and Lung Division, Faculty of Medicine, Imperial College London, Royal Brompton Hospital, London, UK
    Climacteric 8:352-9. 2005
    ..Beneficial effects have been clearly established in previous studies with a 2 mg dose; further evidence was required to confirm the beneficial effects of a 1 mg dose...
  22. ncbi Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk
    F Leyva
    Wynn Department of Metabolic Medicine, Imperial College School of Medicine at the National Heart and Lung Institute, London, UK
    Arterioscler Thromb Vasc Biol 18:928-33. 1998
    ..Further studies are needed to determine whether the insulin-leptin axis plays a coordinating role in this syndrome and whether plasma leptin concentrations could provide an additional measure of cardiovascular risk...
  23. ncbi Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study
    Peter Collins
    Cardiac Medicine, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, UK
    Eur Heart J 27:2046-53. 2006
    ..Randomized trials have not demonstrated coronary heart disease benefit from hormone replacement therapy (HRT). We hypothesized that low-dose HRT may avoid harm...
  24. ncbi Type and route of estrogen administration
    J C Stevenson
    National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London, UK
    Climacteric 12:86-90. 2009
    ..Transdermal HRT may be preferred in women with coagulation disturbances. But, for the majority of women, personal preference should determine their choice of HRT route...
  25. ncbi Effect of postmenopausal oestradiol and dydrogesterone therapy on lipoproteins and insulin sensitivity, secretion and elimination in hysterectomised women
    N A Manassiev
    Menopause Clinic, King s College Hospital, London, UK
    Maturitas 42:233-42. 2002
    ..To investigate in depth the metabolic effects of oestradiol-17 beta both alone and in combination with the progestagen dydrogesterone...
  26. ncbi Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome
    I F Godsland
    Endocrinology, and Metabolic Medicine, Faculty of Medicine, Wynn Department of Metabolic Medicine, Division of Medicine, Imperial College London, London, United Kingdom W2 1NY
    J Clin Endocrinol Metab 90:190-7. 2005
    ..Associations with adiposity and liver enzyme activity suggest the involvement of hepatic fat deposition...
  27. ncbi Optimising delivery systems for HRT
    J C Stevenson
    Imperial College School of Medicine, St Mary s Hospital, Endocrinology and Metabolic Medicine, London, UK
    Maturitas 33:S31-8. 1999
    ..This paper reviews the benefits and disadvantages of some of the main HRT delivery systems currently available...
  28. ncbi Zoladex versus danazol in the treatment of pelvic endometriosis: effects on plasma lipid risk factors
    D Crook
    Cavendish Clinic, London, UK
    Horm Res 32:157-60. 1989
    ..Danazol increased low density lipoprotein and decreased HDL concentrations to give a lipid profile associated with increased risk of CHD...
  29. ncbi Inflammation markers and erythrocyte sedimentation rate but not metabolic syndrome factor score predict coronary heart disease in high socioeconomic class males: the HDDRISC study
    Ian F Godsland
    Faculty of Medicine, Endocrinology and Metabolic Medicine, Imperial College London, London, UK
    Int J Cardiol 97:543-50. 2004
    ..To evaluate prediction of coronary heart disease (CHD) by quantitative measures of the metabolic syndrome and inflammation in a cohort of high socio-economic status males...
  30. ncbi Erythrocyte-derived measures of membrane lipid composition in healthy men: associations with arachidonic acid at low to moderate but not high insulin sensitivity
    C V Felton
    Wynn Institute, Imperial College School of Science, Technology and Medicine, London, UK
    Metabolism 53:571-7. 2004
    ..Measurements in erythrocyte membranes support a role for membrane arachidonic acid content in the modulation of insulin sensitivity, specifically at low/normal insulin sensitivities...
  31. ncbi Effects of oestrogen-only and oestrogen-progestogen replacement therapy upon circulating angiotensin I-converting enzyme activity in postmenopausal women
    Anthony J Proudler
    Department of Endocrinology and Metabolic Medicine, Imperial College School of Medicine, St Mary s Campus, London, UK
    Clin Endocrinol (Oxf) 58:30-5. 2003
    ..However, the relative contribution of each hormonal component to this observation is uncertain. We investigated ACE activity in two groups of healthy postmenopausal women receiving HRT regimens...
  32. ncbi Metabolic effects of hormone replacement therapy
    John C Stevenson
    National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London SW3 6NP, UK
    J Br Menopause Soc 10:157-61. 2004
    ..Such strategies need to be tested in large clinical trials. The metabolic effects of HRTs are key to providing cardiovascular benefit...
  33. ncbi HRT and breast cancer risk: a realistic perspective
    J C Stevenson
    Climacteric 14:633-6. 2011
    ..HRT is a benefit, not a risk, for those women requiring it...
  34. ncbi Effects of equine oestrogens on markers of vasoactive function in human coronary artery endothelial cells
    C S Wingrove
    Wynn Department of Metabolic Medicine, Endocrinology and Metabolic Medicine, Imperal College School of Medicine, St Mary s Medical School, London, UK
    Mol Cell Endocrinol 150:33-7. 1999
    ..We discuss these observations in terms of their potential clinical relevance and use as a means of screening novel oestrogen-like compounds...
  35. ncbi Spotlight on gender
    Peter Collins
    Cardiovasc Res 53:535-7. 2002
  36. pmc Hormone replacement therapy
    John C Stevenson
    BMJ 325:113-4. 2002
  37. ncbi Bone mineral density in postmenopausal women treated with a vaginal ring delivering systemic doses of estradiol acetate
    Farook Al-Azzawi
    Gynecology Research Unit, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK
    Menopause 12:331-9. 2005
    ..To evaluate the effect on bone mineral density of vaginal rings delivering estradiol acetate at two systemic doses versus a locally active vaginal ring in healthy postmenopausal women...
  38. ncbi Further confusion in postmenopausal health: new CSM moves on osteoporosis
    John C Stevenson
    J Br Menopause Soc 10:6-7. 2004
  39. ncbi Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy
    Sven O Skouby
    Frederiksberg Hospital, Department of Ob Gyn, 2000 Copenhagen F, Denmark
    Maturitas 51:8-14. 2005
    ..In contrast, urogenital symptoms may be addressed efficiently and safely with long-term local estrogen therapy...
  40. doi Cardiovascular disease in women
    John C Stevenson
    Menopause Int 14:5. 2008
  41. doi Non-estrogen-based treatments for menopausal symptoms
    Joan Pitkin
    University of Oxford, Oxford OX3 9DU, UK
    Menopause Int 14:88-90. 2008
    ..Treatment of choice should be based on up to-date information and targeted to individual women's needs. Non-hormonal strategies may be useful for women with estrogen-dependent disease such as breast cancer...
  42. ncbi Hormone therapy and heart disease
    John C Stevenson
    Lancet 359:795-6. 2002
  43. ncbi Management of premature menopause
    Joan Pitkin
    Writing Group, British Menopause Society Council
    Menopause Int 13:44-5. 2007
    ....
  44. ncbi Long-term effects of hormone replacement therapy
    John C Stevenson
    Lancet 361:253-4; author reply 254-5. 2003
  45. ncbi Where has WHI led us now?
    John C Stevenson
    Maturitas 48:1-2. 2004